marketcap
Facebook
Twitter
Telegram
Report an ErrorAnnual report 2024
added 12-17-2024
Sonnet BioTherapeutics Holdings Balance Sheet 2011-2024 | SONN
Annual Balance Sheet Sonnet BioTherapeutics Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-18.6 K | -2.07 M | -2.8 M | -27.5 M | -7.35 M | 182 K | 6.15 M | 3.58 M | 10.1 M | 7.82 M | 6.58 M | 436 K | -1.22 M | 1.24 M |
Long Term Debt |
46.6 K | 131 K | 204 K | 30.6 K | - | - | 3.67 M | 852 K | 4.22 M | 1.11 M | 5.01 M | 179 K | - | 236 K |
Long Term Debt Current |
84.3 K | 73 K | 51.3 K | 94.5 K | 82.1 K | 3.3 M | 3.74 M | 5.74 M | 6.17 M | 5.38 M | 1.81 M | 700 K | 236 K | 1.17 M |
Total Non Current Liabilities |
- | - | - | - | - | - | 9.34 M | 4.57 M | 8.46 M | 4.66 M | 7.89 M | 2.79 M | 345 K | 592 K |
Total Current Liabilities |
3.21 M | 5.52 M | 8.16 M | 6.7 M | 4.72 M | 18.1 M | 14.3 M | 14.9 M | 12.1 M | 16.2 M | 11.4 M | 5.53 M | 1.77 M | 3.72 M |
Total Liabilities |
3.26 M | 5.66 M | 8.37 M | 6.73 M | 4.97 M | 2.89 M | 22.4 M | 19.5 M | 20.6 M | 20.8 M | 20.8 M | 8.85 M | 2.12 M | 4.31 M |
Deferred Revenue |
- | - | - | - | 500 K | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-118 M | -110 M | -91.4 M | -61.7 M | - | -12.4 M | -57.1 M | -49.1 M | -42.2 M | -33 M | -20.9 M | -14.5 M | -9.26 M | -6.09 M |
Total Assets |
2.77 M | 5.43 M | 5.83 M | 29 M | 7.99 M | 39.8 K | 29.8 M | 30.2 M | 33.5 M | 42.2 M | 35.8 M | 20.1 M | 7.65 M | 4.8 M |
Cash and Cash Equivalents |
149 K | 2.27 M | 3.05 M | 27.6 M | 7.35 M | 501 K | 630 K | 273 K | 269 K | 1.53 M | 246 K | 443 K | 1.25 M | 152 K |
Book Value |
-486 K | -226 K | -2.54 M | 22.3 M | 3.02 M | -2.85 M | 7.43 M | 10.7 M | 12.9 M | 21.4 M | 15 M | 11.2 M | 5.53 M | 486 K |
Total Shareholders Equity |
-486 K | -226 K | -2.54 M | 22.3 M | 3.02 M | -3.61 M | 7.43 M | 10.7 M | 12.6 M | 21.8 M | 15 M | 11.2 M | 5.53 M | 486 K |
All numbers in USD currency
Quarterly Balance Sheet Sonnet BioTherapeutics Holdings
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
68.8 K | 90.4 K | 111 K | 131 K | 150 K | 169 K | 187 K | 204 K | 221 K | - | 5 K | 30.6 K | 55.5 K | 30.6 K | 103 K | 125 K | 125 K | 6.35 M | 6.63 M | 6.68 M | 6.62 M | 6.77 M | 3 M | 3 M | 3 M | 3 M | 5.74 M | 5.14 M | 4.53 M | 6.01 M | 287 K | 287 K | 287 K | 287 K | 1.1 M | 1.1 M | 1.1 M | 5.65 M | 5.01 M | 5.01 M | 5.01 M | 5.01 M | 399 K | 399 K | 399 K | 399 K | - | - | 232 K | 233 K | 236 K | 236 K | 236 K | 236 K |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
3.18 M | 2.86 M | 2.77 M | 5.66 M | 6.62 M | 7.94 M | 8.48 M | 8.37 M | 6.73 M | 6.51 M | 4.35 M | 6.73 M | 5.81 M | 6.73 M | 5.52 M | 4.97 M | 4.97 M | 4.97 M | 34.7 M | 2.89 M | 38.5 M | 41.1 M | 21.5 M | 21.5 M | 21.5 M | 21.5 M | 18.7 M | 18.7 M | 18.7 M | 18.7 M | 19.8 M | 19.8 M | 19.8 M | 19.8 M | 20.4 M | 20.4 M | 20.4 M | 20.4 M | 20.8 M | 20.8 M | 20.8 M | 20.8 M | 8.85 M | 8.85 M | 8.85 M | 8.85 M | 2.12 M | 2.12 M | 2.12 M | 2.12 M | 4.31 M | 4.31 M | 4.31 M | 4.31 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-115 M | -111 M | -111 M | -110 M | -107 M | -103 M | -97 M | -91.4 M | -84 M | -76.1 M | -67.9 M | -61.7 M | -54.7 M | -61.7 M | -42.6 M | -36.7 M | -36.7 M | -36.7 M | -75.1 M | -12.4 M | -62.3 M | -59 M | -57.1 M | -57.1 M | -57.1 M | -57.1 M | -49.1 M | -49.1 M | -49.1 M | -49.1 M | -42.2 M | -42.2 M | -42.2 M | -42.2 M | -33 M | -33 M | -33 M | -33 M | -20.9 M | -20.9 M | -20.9 M | -20.9 M | -14.5 M | -14.5 M | -14.5 M | -14.5 M | -9.26 M | -9.26 M | -9.26 M | -9.26 M | -6.09 M | -6.09 M | -6.09 M | -6.09 M |
Total Assets |
5.8 M | 5.91 M | 5.34 M | 5.43 M | 10 M | 13.3 M | 4.94 M | 5.83 M | 7.49 M | 15 M | 20.7 M | 29 M | 7.18 M | 29 M | 3.03 M | 7.99 M | 7.99 M | 7.99 M | 31.5 M | 39.8 K | 45.4 M | 48.1 M | 29.8 M | 29.8 M | 29.8 M | 29.8 M | 30.2 M | 30.2 M | 30.2 M | 30.2 M | 33.5 M | 33.5 M | 33.5 M | 33.5 M | 42.2 M | 42.2 M | 42.2 M | 42.2 M | 35.8 M | 35.8 M | 35.8 M | 35.8 M | 20.1 M | 20.1 M | 20.1 M | 20.1 M | 7.65 M | 7.65 M | 7.65 M | 7.65 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M |
Cash and Cash Equivalents |
3.55 M | 3.79 M | 3.02 M | 2.27 M | 7.02 M | 11.4 M | 1.7 M | 3.05 M | 5.22 M | 13.6 M | 19.4 M | 27.6 M | 6.04 M | 27.6 M | 2.35 M | 7.35 M | 7.35 M | 7.35 M | 501 K | 35.7 K | 579 K | 562 K | 524 K | 630 K | 630 K | 630 K | 273 K | 273 K | 273 K | 273 K | 269 K | 269 K | 269 K | 1.18 M | 1.53 M | 1.81 M | 2.81 M | 3.32 M | 246 K | 246 K | 246 K | 246 K | 443 K | 443 K | 443 K | 443 K | 1.22 M | 1.22 M | 1.22 M | 1.22 M | 165 K | 165 K | 152 K | 152 K |
Book Value |
2.62 M | 3.05 M | 2.57 M | -226 K | 3.42 M | 5.37 M | -3.54 M | -2.54 M | 764 K | 8.53 M | 16.4 M | 22.3 M | 1.37 M | 22.3 M | -2.49 M | 3.02 M | 3.02 M | 3.02 M | -3.15 M | -2.85 M | 6.92 M | 6.96 M | 8.26 M | 8.26 M | 8.26 M | 8.26 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 13.7 M | 13.7 M | 13.7 M | 13.7 M | 21.8 M | 21.8 M | 21.8 M | 21.8 M | 15 M | 15 M | 15 M | 15 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M | 5.53 M | 5.53 M | 5.53 M | 5.53 M | 486 K | 486 K | 486 K | 486 K |
Total Shareholders Equity |
2.62 M | 3.05 M | 2.57 M | -226 K | 3.42 M | 5.37 M | -3.54 M | -2.54 M | 764 K | 8.53 M | 16.4 M | 22.3 M | 1.37 M | 2.02 M | -2.49 M | -2.49 M | -2.49 M | -2.49 M | -2.4 M | -2.85 M | 6.01 M | -3.61 M | 7.43 M | 7.43 M | 7.43 M | 7.43 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 12.6 M | 12.6 M | 12.6 M | 12.6 M | 21.4 M | 21.8 M | 21.8 M | 21.8 M | 15 M | 15 M | 15.6 M | 15.1 M | 11.2 M | 9.21 M | 11.2 M | 11.2 M | 5.53 M | 5.53 M | 5.53 M | 5.53 M | 486 K | 486 K | 486 K | 486 K |
All numbers in USD currency